Compare GSK plc (GSK) vs Upstart Holdings Inc (UPST) Price & Performance

GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.

The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.

Upstart Holdings (UPST) trades at $31.72, up 0.83% on the day, with a bearish technical signal and mixed recent earnings. The company reported a significant revenue rebound to $1.02B in 2025 and a return to profitability with $53.60M net income, but Q1 2026 saw an unexpected EPS miss. Analyst consensus is split between Buy and Hold, with a $42.00 price target suggesting potential upside. Recent news highlights the company's AI lending platform expansion and a key $600M funding deal.

The outlook hinges on execution of its AI-driven lending model amid margin pressures. Investment opportunity lies in the company's revenue growth and expanding product lines, but risks include volatile cash flows, high debt levels, and sensitivity to funding markets and economic cycles. The stock's high P/E ratio of 77.05 demands sustained high growth to justify valuation.